Of particular note, in a primary/metastatic pair of colorectal cancer samples, we found that the colorectal metastatic samples showed a ~ 20% increase in methylation in the EBF3 promoter and a ~ 20% decrease in methylation at most sites in the gene body, which echoes previous observations made regarding the analysis of the EBF3 promoter and the EBF3 gene body in two independent studies of melanoma metastases [9, 10]. The gene discussed is EBF3; the disease is colorectal cancer.